How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →

Biotheryx Announces Data from its Phase 1 Dose Escalation Study of BTX-9341, a First-in-Class, Potent and Selective CDK4/6 Degrader, for the Treatment of Advanced/Metastatic HR+/HER2- Breast Cancer

calendar_today May 18, 2026 person biotheryx domain biotheryx

San Diego, CA, May 18, 2026 — Biotheryx, Inc., a biopharmaceutical company focused on the discovery and development of first-in-class[…] Read More